IRCT2014101618966N2 IRCT 2014-10-23 No sponsor The treatment of retinopathy of prematurity with Avastin The Prevention of Blindness in Retinopathy of Prematurity by Intravitreal Injection of Bevacizumab 2012-01-01 anticipated 40 Complete https://irct.ir/trial/17073 interventional Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment. N/A Retinopathy of prematurity. A dose of bevacizumab of 0.625 mg in 0.025 ml was injected in each eye from the study sample, according to the following protocol: The pupils were dilated with a mixture of tropicamide 0.5% and phenylephrine 0.5%. Anesthesia was achieved with 0.5% proparacaine hydrochloride administered topically, 3 times, every 2 minutes before the injection. Every eye was prepared in a sterile manner using 5% povidone iodine which was also instilled in the eye 3 minutes prior the injection. A nurse hold the infant's head during the procedure and 0.025 ml of bevacizumab (0.625 mg) were injected in pars plicata, 1.5 - 1.75 mm away from the limbus, with a 30 G needle, perpendicularly on the globe initially and then slightly directed toward the center of the eyeball. After the injection, the patients received topical tobramycin, 5 times/day, for 3 days. The patients were re-examined the next day and then every week to monitor the regression of the disease. The follow-up continued for 52 weeks, every 1 or 2 weeks until full vascularization of the retina was observed. Full vascularization was defined as follows: vascularization as far as it would develop without an active component or clinically significant tractional elements. All the treatments were carried out by the same physician and the examinations were performed by three ophthalmologists experienced in ROP..